predicted severe acute pancreatitis severe acute pancreatitis
Conditions
Interventions
Standard treatment and Tocilizumab 4 mg/kg IV *1 dose
,Standard treatment and NSS 100 ml IV drip
Experimental Drug,Placebo Comparator No treatment
Tocilizumab,placebo
Sponsors
Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Predicted severe acute pancreatitis at admission, defined by at least one of 1. BISAP equal or more than 3 2. End organ failures by Modified Marshall scoring system
Exclusion criteria
Exclusion criteria: ALT or AST > 5x UNL onset of pancreatitis more than 72 hours severe acute pancreatitis at admission Severe cholangitis Chronic pancreatitis Cardiomyopathy (EF < 30) or active heart failure Active/uncontrolled infection Terminal cancer Hypersensitivity Previous treatment with tocilizumab Pregnancy Inability or unwillingness to provide consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Actual severe acute pancreatitis 48 hour after admission Defined by Revised Atlanta Classification | — |
Secondary
| Measure | Time frame |
|---|---|
| mortality rate in admission death,adverse event rate in admission adverse event rate,length of hospital stay in admission day,length of ICU stay in admission day,local complication in admission Defined by Revised Atlanta classification | — |
Countries
Thailand
Contacts
Public ContactParit Mekaroonkamol
Chulalongkorn University
Outcome results
None listed